Our diverse team of researchers are pushing the boundaries of science and are aiming to impact the health of our community for generations to come. Check back often as our team grows.
Dr. Alexandra Binnie, Critical care physician and lead for ICU research |
|
Dr. Alexandra Binnie is a critical care physician and a leading figure in ICU research. Alongside her clinical duties, Dr. Binnie holds the position of Invited Assistant Professor at the University of Algarve and serves as an intensivist at the Centro Hospitalar Universitário do Algarve in Portugal. Her expertise lies in the pathophysiology of sepsis and multiple organ dysfunction syndrome, particularly focusing on the role of epigenetics in driving the inflammatory response to infection. Dr. Binnie's dedication to advancing critical care extends beyond the bedside. She is a co-founder of the Canadian Community ICU Research Network (CCIRNet), a pioneering initiative aimed at bolstering research capabilities in community ICUs across Canada. In her role as co-chair of CCIRNet, Dr. Binnie has been instrumental in developing the community hospital research toolkit, an accessible resource designed to facilitate the establishment and maintenance of research programs in community hospitals. With a passion for knowledge-sharing and a commitment to enhancing research opportunities beyond Osler's walls, Dr. Binnie's contributions have made a significant impact on critical care research both domestically and internationally. Her multifaceted approach to patient care, education, and research underscores her status as a leader in the field, driving advancements in critical care medicine and fostering collaboration within the health care community. |
Dr. Sergio Borgia, Infectious Diseases Consultant |
|
Dr. Sergio Borgia, MD, MSc, FRCP(C) is an Infectious Diseases Consultant at Osler. He is a physician and researcher with a focus in infectious diseases and molecular genetics. He completed his graduate work in Molecular Genetics and Microbiology at Mount Sinai Hospital in Toronto, studying hemolytic toxin expression of Group A Streptococci and obtained his medical degree from Queen’s University. He undertook specialty training in Internal Medicine and Infectious Diseases at McMaster University. He is a Fellow of the Royal College of Physicians of Canada and is an Assistant Clinical Professor in the Department of Medicine and Infectious Diseases at McMaster University. Dr. Borgia’s clinical and research interests have a particular focus on infection prevention and control of multi-drug resistant bacteria, viral Hepatitis and Tuberculosis. He has made significant contributions to the field, including working with a team to describe the first outbreak of Carbapenemase-producing Enterobacteriaceae in the Americas and co-founding a multi-disciplinary Tuberculosis clinic in collaboration with Peel Public Health. He continues to conduct quality improvement initiatives in the delivery of comprehensive care for latent and active Tuberculosis including multi-resistant Tuberculosis. He is the Medical Director of the Osler Hepatitis Centre providing care to patients with viral Hepatitis and the former co-chair of the pharmacy and therapeutics committee. Dr. Borgia’s research focuses on integrated cross-disciplinary models of care for viral Hepatitis. The team participates in clinical trials, including burden of illness, and efficacy of novel therapeutic all-oral treatment regimens as well as treatments in Hepatitis Delta. Other research areas have included systematic cost-effectiveness analyses of Hepatitis C treatments and care delivery models as well as models of Hepatitis C elimination strategies in Canada. With colleagues, his group was the first to discover a new Hepatitis C genotype. He is a recent member of the Canadian Hepatitis B Network. He served as a former coroner in the Region of Peel and as an ad hoc consultant to Peel Public Health. He has acted as a faculty member for CARE-Liver Canada, MedScape/WebMD and has published in numerous peer-reviewed journals as well as serving as a reviewer for various Infectious Diseases and Hepatology publications. During the COVID-19 pandemic, Dr. Borgia participated in national and international collaborations in COVID-19 trials that have seen publication in the Lancet, Respiratory Medicine and the New England Journal of Medicine. Dr. Borgia believes in strong patient advocacy for Peel Region’s residents and seeks to increase access to health care resources, innovative treatments and cross-disciplinary models of care. He is considered a leader in the field of Infectious Diseases. |
Dr. Martin Robert Chasen, Medical Director of Palliative Care |
|
Dr. Martin Robert Chasen stands out in the field of palliative care and oncology, renowned for his extensive expertise and significant contributions to patient care, research, and education. Serving as the Medical Director of Palliative Care at Osler in Brampton and Etobicoke since July 2015, Dr. Chasen has been instrumental in enhancing the quality of life for patients facing life-limiting illnesses. In addition to his role as Medical Director, Dr. Chasen holds several prominent positions, including Regional Clinical Co-Lead for the Central West Palliative Care Network and Clinical Lead for Research at Osler. His commitment to advancing palliative care extends to his involvement as the Site Lead for the Residency program for the Royal College Palliative Medicine Program at the University of Toronto. Dr. Chasen's academic appointments further underscore his dedication to education and research. He currently serves as an Associate Professor in the Department of Medicine at the University of Toronto and as an Adjunct Professor in the Faculty of Health Sciences and Medicine at Bond University, Gold Coast, Australia. Additionally, he is the Clinical Professor is the Department of Family Medicine at McMaster University and holds associate and adjunct professorships at the University of Ottawa, and McGill University. Throughout his career, Dr. Chasen has had numerous accolades and awards for his outstanding contributions to oncology and palliative care. These include the prestigious Elizabeth J. Latimer Prize in Palliative Care from McMaster University in 2017, the Kay Blair Community Service Award from Osler in 2017, and the "Heroes in the Home" Caregiver Recognition Award from the Central West Local Health Integration Network in 2018. Driven by a passion for improving patient outcomes and advancing the field of palliative care, Dr. Chasen continues to make significant strides in cancer care, family caregivers support, quality improvement and survivorship research. His dedication, expertise, and commitment to compassionate patient care make him a true leader in the field of palliative medicine. |
Dr. Parneet Cheema, Medical Director of Cancer Care and Head of Cancer Research |
|
Dr. Parneet Cheema, MD, MBiotech, FRCPC, is the lead of cancer care as Osler’s Medical Director of Cancer Care and Head of Cancer Research. With a background in medical oncology, Dr. Cheema's journey began with postgraduate training at the University of Toronto, where she currently holds the position of Assistant Professor in the Department of Medicine. Her academic experience goes beyond traditional medical training, as evidenced by her interdisciplinary business and science master’s degree in biotechnology from the University of Toronto. Dr. Cheema's expertise in lung cancer, precision medicine and immunotherapy has gained her international recognition for her contributions. Dr. Cheema has been an innovator in her field, under her leadership, groundbreaking initiatives like the Osler Cancer Immunotherapy Program have been established, revolutionizing cancer treatment. She has put Osler at the head of oncology clinical trials recruitment in Canada, ensuring patients have access to state-of-the-art treatments through global clinical trials. Her close collaborations with the Osler Pathology Department have promoted the integration of cutting-edge genomics into cancer care at Osler. She has also solidified partnerships that enable Osler to offer the most advanced genomic technologies for cancer care nationwide. With a strong portfolio of clinical trials and research papers, Dr. Parneet Cheema has made significant contributions to the field of oncology. Her work includes publications in prestigious journals like the New England Journal of Medicine and issuing several Canadian consensus statements on lung cancer treatments. She has also served as a steering committee member for global clinical trials. Dr. Cheema has played a pivotal role in advancing personalized and innovative oncological treatments both at Osler and on a broader scale. |
Dr. Paula Chidwick, Director Ethics Research |
|
Dr. Paula Chidwick currently serves as the Director of Ethics at Osler. Committed to fostering trusting partnerships with diverse communities, she endeavors to develop innovative ethical solutions to the complex challenges within health care. Dr. Chidwick holds a Ph.D. in Philosophy with a specialization in Bioethics from the University of Guelph. She was the inaugural Director of Ethics at Osler, making her the first in a community hospital setting across Canada. She is also the founding Director of the Ethics Quality Improvement Lab, established in 2017. She holds certificates in Adaptive Leadership from Harvard University, Integrative Thinking from the Rotman School of Management, Cultural Safety from the Indigenous Primary Healthcare Council and San'yas, and a certification in Health Policy, Management and Evaluation from the Dalla Lana School of Public Health Institute. Dr. Chidwick brings a unique perspective to her role. Her dedication to advancing ethical practices has garnered significant recognition, including securing over $1.8 million in contributions and grants supporting innovative work and research in the areas of ethics quality improvement, ethics in transitions, and end–of–life. In Fall of 2020, the Ethics Quality Improvement team, under Dr. Chidwick's leadership, was awarded a World Health Organization Ethics Grant to conduct a global survey on ethical issues in long-term care during the COVID-19 pandemic. Dr. Chidwick's impact extends beyond Osler, as she has served on numerous panels and committees, including the Canadian Bioethics Society Executive, Health Canada's Scientific and Expert Advisory Panels, MOHLTC Critical Care Coaching Teams, and Critical Care Services Ontario. She is also a founding member of several collaborative initiatives, including the Healthcare Consent Quality Collaborative, Regional Bioethics Groups (RBG, RBG North), and the Ontario Ethics Quality Improvement Network. Her contributions to the field of health care ethics have been recognized through various awards and honours, including Accreditation Canada Leading Practices, World Health Organization grants, and Minister Medal Honor Roll acknowledgments. Dr. Chidwick's commitment to excellence is evident in her extensive professional activities, encompassing roles in education, training, and consultancy across various health care institutions and organizations. Dr. Chidwick's commitment to ethical leadership and her ongoing efforts to address critical ethical issues in health care greatly contribute to the medical community's collective efforts. Through her visionary leadership and collaborative approach, she continues to shape the landscape of health care ethics, ensuring the delivery of compassionate and ethically sound care to patients and communities alike. |
Dr. Henry J. Conter, General Medical Oncologist/Hematologist |
|
Dr. Henry Conter is solving seemingly impossible problems in health care by reshaping how individuals engage with their health care journeys, ultimately improving outcomes. Currently serving as the Portfolio Manager of Early Development Oncology within the Pharmaceuticals Research and Early Discovery division at Hoffman La-Roche, Dr. Conter spearheads clinical trial designs that prioritize the needs of patients, clinicians, and their advocates. He also maintains an active role as a practicing General Medical Oncologist/Hematologist at Osler. Prior to his tenure at Roche, Dr. Conter gained a track record marked by innovation and leadership excellence. Holding pivotal roles such as Chief of Hematology/Oncology, Medical Director of the Cancer Health System, and Executive Medical Director of Quality, Patient Safety, and Health System Integration at Osler, he led transformative initiatives that elevated standards of care. He also represented oncology interests on influential panels like the Ontario Steering Committee for Cancer Drugs and the pan-Canadian Oncology Drug Review Expert Review Panel, as well as serving on various advisory bodies. Dr. Conter's academic journey underscores his multidisciplinary approach to health care. After earning his undergraduate degree in Mechanical Engineering from the University of Western Ontario, he pursued his passion for medicine, obtaining his MD from McMaster University. He then completed his clinical residency in Internal Medicine at the University of Alberta, where he earned an MSc in Health Technology Assessment. Dr. Conter further honed his expertise through a clinical fellowship in Medical Oncology at the University of Texas M.D. Anderson Cancer Center, coupled with a Masters in Finance from the University of Houston. Throughout his career, Dr. Conter has continuously expanded his knowledge and skill set through a commitment to ongoing education. His impressive list of certifications and continuing education endeavors reflects his dedication to staying current with emerging trends and best practices in health care leadership, management, and innovation. In addition to his professional responsibilities, Dr. Conter has played integral roles in numerous administrative and service capacities, contributing significantly to organizations like Hoffman-La Roche, Osler, and various health care committees and associations. His honours include prestigious awards from renowned institutions, affirming his commitment to excellence in patient care and health care advancement. With a relentless drive to tackle complex healthcare challenges and a steadfast dedication to improving patient outcomes, Dr. Henry Conter continues to be a transformative force in the field of oncology and even beyond. |
Dr. Shaan Dudani, Medical Oncologist |
|
Dr. Shaan Dudani is a Medical Oncologist with Osler and an Assistant Professor in the Department of Medicine at the University of Toronto. He treats patients with genitourinary and gastrointestinal malignancies and serves as the GI oncology site lead at Osler. He completed medical school at the University of Birmingham in the United Kingdom followed by Internal Medicine and Medical Oncology residencies at the University of Ottawa. He then pursued a two-year clinical and research fellowship in genitourinary oncology at the Tom Baker Cancer Centre and University of Calgary and completed a Master’s in Public Health from the Harvard University T.H. Chan School of Public Health. In the field of cancer research, Dr. Dudani has contributed through his involvement in clinical trials and outcomes research. As the local principal investigator for various gastrointestinal trials, he plays an important role in advancing treatment options for patients. His research interests include health outcomes and effectiveness research using real-world data, with a focus on cancers such as kidney, rectal, and lung cancers. Dr. Dudani has also made significant contributions to biomarker development for personalized treatments for patients. Throughout his career, Dr. Dudani has been recognized for his outstanding contributions to oncology. His honours include awards such as the Novartis Oncology Young Canadian Investigator Award and American Society of Clinical Oncology Conquer Cancer Foundation Merit Awards. As a clinician, researcher, and educator, Dr. Shaan Dudani is committed to excellence in cancer care and helping to shape his clinical practice with the latest research. |
Dr. Tina Hu, Family Medicine |
|
Dr. Tina Hu is a dedicated family physician based in Toronto, known for her commitment to patient-centered care, research, and advocacy for marginalized populations. Having completed her medical degree, residency, and Master of Science degree at the University of Toronto, Dr. Hu has established herself in the field of family medicine, with a particular interest in addiction medicine and caring for vulnerable communities. Dr. Hu's outstanding contributions to research have been recognized with many awards, including the 2018 University of Toronto Postgraduate Medical Education Postgraduate Research Award and the Family Medicine Resident Award from The College of Family Physicians of Canada. Her research endeavors focus on improving health outcomes and quality of care for patients, with projects ranging from delirium management in elderly patients to telepsychiatry services for children and adolescents in remote areas of Ontario. In her award-winning research within The General Medicine Inpatient Initiative, Dr. Hu investigated delirium and transitions of care, aiming to enhance communication between inpatient and outpatient physicians and develop delirium-specific discharge recommendations. Through her work, she sought to address the under-recognition of delirium in the medical community and improve outcomes for patients during high-risk transitions of care. Additionally, Dr. Hu's worked on a telepsychiatry program evaluation highlights her commitment to providing accessible mental health services to underserved communities, particularly remote Indigenous populations. Her innovative approach utilizes telemedicine to deliver urgent psychiatric consultations, reducing the need for travel and improving access to care for vulnerable youth. Dr. Hu's passion for family medicine stems from her desire to make a meaningful difference in the lives of her patients and communities. Her experiences working with marginalized populations, both during her undergraduate studies and as the executive director of IMAGINE, a student-run interprofessional clinic, have shaped her dedication to addressing social determinants of health and advocating for equitable access to health care. Driven by a deep appreciation for primary care and the opportunity to build long-term relationships with patients, Dr. Hu believes in the transformative power of family medicine in promoting preventive healthcare and addressing the diverse needs of individuals and communities. Her commitment to compassionate, comprehensive care exemplifies her dedication to improving health outcomes and advancing the field of family medicine. |
Dr. Marco Iafolla, Medical Oncologist |
|
Dr. Marco Iafolla is a Medical Oncologist at Osler, specializing in cutaneous, head and neck, and genitourinary cancers. His academic journey began at the University of Toronto where he completed his Bachelors of Science in Biological Chemistry and Masters of Science in Physical Chemistry. He then pursued his medical education at the University of Ottawa, followed by residencies in Internal Medicine at the University of Alberta and Medical Oncology at McMaster University. Dr. Iafolla's dedication to advancing cancer care led him to complete a clinical research fellowship at the Princess Margaret Cancer Centre, focusing on immuno-oncology drugs in early phase clinical trials and biomarker development. Since joining Osler in September 2019, he has been actively engaged in biomarker development research to enhance patient outcomes and treatment strategies. His research activities primarily revolve around immuno-oncology biomarker development, with a focus on identifying patients who are likely to benefit from treatment. Currently, Dr. Iafolla is leading several groundbreaking projects, including a pilot study to evaluate the feasibility of biobanking non-invasive samples from advanced urothelial carcinoma patients and investigating BRAF-mutant circulating tumor DNA as a predictive and prognostic biomarker in various cancers. Dr. Iafolla's contributions to cancer research have been recognized with prestigious awards, including the ASCO Merit Award and the Novartis Oncology Young Canadian Investigator Awards. His project, "Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients treated with single agent pembrolizumab," has garnered acclaim for its innovative approach to personalized cancer therapy. In addition to his role at Osler, Dr. Iafolla serves as an Assistant Professor at the University of Toronto, where he continues to inspire and mentor future generations of oncologists. Dr. Iafolla's dedication to advancing cancer care through research and clinical practice embodies his passion for improving outcomes and quality of life for cancer patients. |
Dr. Masud Khandaker, Division Head of Cardiology |
|
Dr. Masud Khandaker joined Osler in 2016 as a staff cardiologist and is the current Division Head of Cardiology and Medical Director of the Cardiovascular Health System at Osler, a role he has held since 2021. Over the course of his career, Dr. Khandaker has becoming increasingly involved in leadership roles holding the positions of Physician Lead for Ambulatory and Diagnostic Cardiology and Cardiac Rehabilitation as well as the Medical Director of the Echocardiography Labs at Osler since 2020. He has also served as the Physician Lead of Cardiology at Peel Memorial since 2017. Dr. Khandaker completed his Ph.D. in Microbiology and Immunology at the University of Western Ontario and completed his medical degree at the National University of Ireland. He then completed both his internal medicine residency and cardiology residency training at the Mayo Clinic in Rochester, Minnesota. Dr. Khandaker subsequently completed a two year cardiology subspecialty fellowship at the Mayo Clinic in advanced cardiac imaging including advanced training in echocardiography, nuclear cardiology, cardiac CT and cardiac MRI. Dr. Khandaker has held an academic title of Assistant Professor of Medicine at the Mayo Clinic from 2009-2014. He joined the University of Ottawa Faculty of Medicine as a Lecturer from 2012-2016 and staff cardiologist and Medical Director of the Echocardiography Lab at the Montfort Hospital in Ottawa (French academic hospital) from 2012-2016. As a member of the Cardiology team at Osler, Dr. Khandaker has been involved in many clinical initiatives to improve patient care including the enhancement of the cardio-oncology pathway and improving response time to critical patient events on the cardiology ward. However, Dr. Khandaker's biggest contribution to Osler has been in the advancement of structural heart disease interventions (valvular heart disease and PFO/ASD closure). He has worked very hard over the years to introduce and advance Osler's 3D TEE imaging program for structural heart disease. He has been developing collaborative pathways to increase access and timely care for structural heart interventions for Osler patients with the goal of bringing a structural heart disease program to Osler. Dr. Khandaker has contributed to over 50 peer reviewed journal articles, book chapters and abstracts, many in high impact journals. He has given more than 40 presentations at international, national and regional meetings. In addition to general cardiology, his current clinical and research interests include complex valve disease, cardiomyopathies, pericarditis, spontaneous coronary artery dissection and cardio-oncology. He has also been involved in increasing awareness of cardiovascular disease in the South Asian community. Dr. Khandaker is recognized by his peers for academic level expertise with level three echocardiography and cardiac CT/MRI. He is often called upon to help with complex imaging interpretation and the management of complex cardiac patients. |
Dr. Philip George Kuruvilla, Division Chief of Hematology |
|
Philip George Kuruvilla, distinguished in the field of hematology and medical oncology, currently serves as the Division Chief of Hematology at Osler, while also holding the role of Medical Oncologist. Additionally, he holds the position of Assistant Clinical Professor (Adjunct) at McMaster University, where he contributes significantly to medical education and research. Dr. Kuruvilla pursued his medical education at the University of Toronto, where he obtained his M.D. in 1986. Following this, he completed his internship at Toronto Western Hospital and his residency at Toronto Western and General Hospitals. Dr. Kuruvilla further specialized in Medical Oncology through a fellowship at Princess Margaret Hospital in Toronto, where he served as Chief Resident in 1991. Throughout his career, Dr. Kuruvilla has held several prominent positions, including Division Chief of Hematology and Medical Oncology at Osler from 2008 to 2013. He also served as Supervisor at the Royal College of Physicians and Surgeons and Regional Quality Lead at Cancer Care Ontario during the same period. Notably, Dr. Kuruvilla has been an active member of various medical associations, including the Royal College of Physicians and Surgeons of Canada, the Ontario Medical Association, the American Society of Hematology, and the American Society of Oncology. Dr. Kuruvilla's academic qualifications and certifications underscore his expertise in the field, including his F.R.C.P.C. in Internal Medicine and Medical Oncology. He has also been actively involved in clinical research, serving as the Primary Investigator in numerous trials aimed at advancing treatments for various cancers, such as chronic lymphocytic leukemia and diffuse large B-cell lymphoma. In addition to his clinical and research endeavors, Dr. Kuruvilla has contributed significantly to medical education, mentoring aspiring healthcare professionals and fostering a culture of excellence in patient care. His dedication to improving oncological care has earned him widespread recognition and respect within the medical community. His commitment to excellence, coupled with his compassionate approach to patient care, continues to make a profound impact on the field of hematology and medical oncology. |
Dr. Hina Marsonia, Clinical Pharmacist, Residency Coordinator, Complex Medicine Clinic |
|
Dr. Hina Marsonia is an innovative pharmacist with a wide range of clinical expertise and a commitment to advancing patient care through innovative research and education. Currently serving as the Clinical Pharmacist for the complex medicine clinic at Osler, Dr. Marsonia has been active in pioneering initiatives that integrate technology to enhance chronic disease management. Dr. Marsonia earned her Doctorate of Pharmacy from the University of Colorado and holds a Bachelor of Science in Pharmacy from the University of Toronto. She has been an active member of various professional organizations over the years including the Canadian Hospital Society for Pharmacists, Ontario College of Pharmacist Professional Practice Committee. Standing out amongst her accomplishments is her leadership in developing and implementing a remote management platform for patients with chronic diseases. The platform includes real-time clinical decision support tools designed to empower patients in self-management, foster engagement, and improve communication between healthcare providers and patients. Dr. Marsonia's work addresses a critical gap in managing comorbidities between scheduled clinical appointments, particularly in complex settings like the complex medicine clinic. This platform is now being used across multiple organizations and community programs such as with paramedicine teams to manage patients with congestive heart failure and chronic obstructive pulmonary disease. Dr. Marsonia received the Chanderkalli Chatoori Award of Excellence Professional Practice Award in 2024, highlighting her leadership and innovation in pharmacy practice and she continues to drive advancements. |
Dr. Shailesh K. Nadkarni, Clinical Program Director, Seniors Health, Rehabilitation, Complex Continuing Care and Transitional Care |
|
Dr. Shailesh K. Nadkarni currently serves as the Clinical Program Director, Seniors Health, Rehabilitation, Complex Continuing Care and Transitional Care, at Osler. Dr. Nadkarni plays an important role in strategic leadership and is recognized for developing innovative strategies for achieving exceptional patient care. Dr. Nadkarni's career is marked by contributions to novel healthcare initiatives, which includes supporting the Butterfly Model of Care. This model emphasizes compassionate, patient-centered care and sees emotional wellbeing as important as physical health. Dr. Nadkarni's leadership has been instrumental in driving quality improvement initiatives and achieving operational excellence across diverse healthcare settings. He has received numerous awards to his own credit or as a part of a team, including the Osler's Innovation Value Award and the Leading Practices Award from Health Standards Organization - Accreditation Canada, which reflect his commitment to innovation and excellence in healthcare delivery. Beyond his program responsibilities, Dr. Nadkarni is recognized for his mentorship and supervision of students. To add to his growing list of publications, he has recently published an abstract through the Summer Student Research Program in a peer reviewed journal and currently supervising a research assistant that graduated from the program. He is a respected member of various professional associations and boards. Dr. Nadkarni continues to influence healthcare policy development while championing health equity, patient safety and care. His expertise, academic contributions and dedication make him a notable researcher in the field of older adult care. |
Theresa Nitti, Provincial PoET Program Coordinator |
|
Theresa Nitti, RPN, serves as the Provincial PoET (Prevention of Error-based Transfers) Program Coordinator at Osler, bringing with her a wealth of experience from various health care settings. With a background spanning family practice, supportive housing, adult day programs, long-term care, and hospital environments, Theresa's expertise is vast and diverse. At Osler, Theresa has held nursing positions on both Palliative and General Medicine units, where she facilitated multiple safety and quality improvement initiatives. Her journey then led her to become the Spread Leader for the PoET Southwest Spread Project, a collaborations between Osler’s Ethics Quality Improvement Lab and McMaster University’s Department of Family Medicine. Theresa's dedication to advancing health care ethics is evident through her contributions to various projects and initiatives. She presented at the World Congress for Public Health in Rome, where she shared insights from the publication "Ethical Issues in Long-term Care in Low-, Middle- and High-Income Countries During the COVID-19 Pandemic." Additionally, Theresa was invited to speak to a graduating class of nurses at the Humber College Career Summit. In her current role as the Provincial PoET Program Coordinator, Theresa focuses on spreading and implementing PoET’s ethics quality improvement project across long-term care homes throughout Ontario. Her responsibilities include supporting launch activities, providing training and education to staff and physicians, and facilitating discussions with residents and family members. Through adaptive leadership and change management skills, Theresa aims to align practices in long term care with Ontario’s Health Care Consent Act legislation, thereby reducing consent-related errors. Theresa's commitment to resident-focused care, coupled with her extensive clinical experience underscores her dedication to enhancing health care delivery, research and ethical practices. |
Dr. Jill Oliver, Community Ethicist and PoET Project Lead, Ethics Quality Improvement Lab |
|
Dr. Jill Oliver brings a wealth of knowledge and expertise to her role as the Community Ethicist and PoET Project Lead. With a PhD in Philosophy from the University of Waterloo, she focuses on navigating complex ethical dilemmas, particularly within the realm of long-term care settings. Throughout her academic journey, Dr. Oliver has been committed to understanding and addressing critical issues surrounding consent, capacity, substitute decision making, and end-of-life care. Her academic pursuits include an Academic Fellowship in Clinical and Organizational Ethics from the University of Toronto Joint Centre for Bioethics, with hands-on experience gained in a number of health-care settings, including Mount Sinai, Toronto Rehab, Sunnybrook Hospital and Trillium Health Partners. Dr. Oliver's dedication to applying her expertise in real-world settings is evident in her extensive internships in clinical ethics at renowned institutions such as the Baycrest Centre for Geriatric Care and Osler. These experiences have provided her with invaluable insights into the practical challenges faced by health care professionals and patients alike, informing her approach to ethical decision-making and quality improvement initiatives. Currently, Dr. Oliver is spearheading the PoET Project. This groundbreaking initiative aims to enhance ethics-related quality improvement measures within the health care system, ensuring that patients receive the highest standard of care while upholding ethical principles and values. Beyond her academic and professional accomplishments, Dr. Oliver is a lifelong learner, continuously seeking opportunities to expand her knowledge and skills. Her pursuit of further education, including a certificate in Elder Law from York University - Osgoode Hall Law School and a program in The Art and Practice of Adaptive Leadership from Harvard University, underscores her goal of excellence and innovation in her field. Dr. Oliver's advocacy for ethical health care practices extends beyond academia. Her contributions have left an impact on the lives of patients, families and health care providers, fostering compassion, integrity and excellence. As a leading expert ethicist in long-term care settings, she is dedicated to advancing ethical health care practices and enhancing patient outcomes. |
Dr. Angel Petropanagos, Ethics Researcher, Ethics Quality Improvement Lab |
|
Dr. Angel Petropanagos is an Ethics Researcher at the Ethics Quality Improvement (EQI) Lab. With a PhD in philosophy from Western University, specializing in bioethics and feminist theory. She is deeply engaged at the intersection of ethics and health care decision-making. Her postdoctoral fellowship in bioethics at Novel Tech Ethics, Faculty of Medicine, Dalhousie University, solidified her expertise in the field. As the Interim Communications Officer for the Canadian Bioethics Society and the Co-Managing Editor of Impact Ethics, Angel is committed to fostering dialogue and sharing insights within the bioethics community. She is also a co-founder and co-chair of the Ontario Practicing Healthcare Ethicists Community of Practice, demonstrating her dedication to advancing ethical practices in health care. Dr. Petropanagos' clinical ethics work emphasizes a patient-centered approach and the importance of role clarity in health care decision-making. Her contributions extend beyond research and academia; she actively engages in creating practical tools and resources to support individuals, teams, and organizations in making ethically sound decisions. Having completed Health Quality Ontario's IDEAS Advanced Learning Program, Dr. Petropanagos is at the forefront of developing, implementing, and scaling EQI projects such as the Checklist for Ethical and Legal Obligations and the PoET project. These initiatives exemplify her commitment to improving ethical decision-making processes in health care settings. Dr. Petropanagos' publication record focuses on various topics in bioethics, including reproductive ethics, informed consent, medical assistance in dying, and health technology assessments. Her expertise is consulted in national and international policy discussions, where she provides valuable insights into complex ethical issues. As a respected educator, Dr. Petropanagos has taught courses in bioethics, critical thinking, and philosophy at various institutions, including the University of Toronto and Humber College. She also contributes to clinical ethics education through guest lectures and workshops, ensuring that health care professionals are equipped with the knowledge and skills to navigate ethical challenges effectively. Dr. Petropanagos' involvement in committees, working groups, and professional organizations reflects her commitment to shaping ethical practices and policies in health care. She will also be presenting Ethical Preparedness: AI and the Survivability of Research Ethics Boards at the upcoming International Conference on Clinical Ethics and Consultation and Canadian Bioethics Society in Montreal. |
Dr. Leila Salehi, Emergency Medicine |
|
Dr. Salehi completed her undergraduate medical education at McGill University School of Medicine and her postgraduate training in Family Medicine at the University of Toronto, where she obtained her CCFP certification. Dr. Salehi further specialized in Emergency Medicine, completing the CCFP(EM) program at McGill University. Complementing her clinical expertise, Dr. Salehi holds dual master's degrees, one in Health Policy and Administration from the Mailman School of Public Health at Columbia University and another in Public Health from the Dalla Lana School of Public Health at the University of Toronto. These academic pursuits have equipped her with a comprehensive understanding of health care systems and policy frameworks. Throughout her career, Dr. Salehi has been active in research, particularly focusing on topics such as emergency department overcrowding, physician practice patterns, and diagnostic imaging utilization. As the Corporate Director of Research in Emergency Medicine at Osler, she led numerous research projects, resulting in several peer-reviewed publications, research abstracts, and conference presentations. Her research has been recognized through several awards, including the CAEP-CanVECTOR Research Abstract Award and the Michael Garron Hospital Publication Award. In addition to her research endeavors, Dr. Salehi serves as an Assistant Clinical Professor at McMaster University and an Assistant Professor at the University of Toronto. Furthermore, she has held various administrative roles within Osler in the areas of Emergency Department flow and quality improvement, demonstrating her commitment to improving patient care and health care delivery systems. |
Dr. Brandon Sheffield, Pathologist, Division of Advanced Diagnostics |
|
Dr. Brandon Sheffield is an anatomical pathologist with expertise and a primary focus on molecular genetic pathology. His commitment to advancing personalized cancer treatments through the application of molecular genetics on an individual patient basis has significantly contributed to the field of oncology. Dr. Sheffield's educational journey is marked by excellence and dedication, beginning with the President's Scholarship from the University of Western Ontario in September 2004. Driven by a passion genetics, he completed the Genetics program at Western University 2007 and earned his Doctor of Medicine from the University of Toronto in 2011. Subsequently, pursing a specialization in Pathology from The University of British Columbia in 2016. His contributions have been acknowledged through numerous honors and awards. Notably, he was recognized as part of the Brampton Top 40 Under 40 in September 2019, a testament to his leadership and impact in the community. In 2016, he received the Changemaker Award from Doctors of BC, recognizing his significant contributions to health advocacy. His accomplishments in research have been internationally recognized, receiving the Young Investigator Award from the International Association for the Study of Lung Cancer in September 2015. Dr. Sheffield's commitment to clinical research in lung cancer was recognized with the Dutkevich Memorial Pathology Award from the University of Calgary in October 2010. He has received several other awards and honours. During his time working with Osler, Dr. Sheffield highlighted his commitment to advancing healthcare through his role in acquiring Osler's newest next-generation sequencing technology, underscoring his dedication to advancing clinical research and enhancing patient care. In the field of anatomical pathology Dr. Sheffield is continually pushing the boundaries of molecular genetic pathology to improve personalized cancer treatments and advance clinical research for the benefit of patients in the Brampton community and beyond. |
Dr. Sohel Somani, Surgical Lead, Ophthalmology |
|
Dr. Sohel Somani is a recognized ophthalmologist renowned for his expertise in medical retina and cataract surgery. His journey in the field of medicine began at the University of Toronto, where he earned his Doctor of Medicine degree after completing his pre-medical studies at the Faculty of Pharmacy. Dr. Somani then pursued a residency in Ophthalmology at the University of Toronto, followed by a fellowship in Medical Retina at the same institution. Since 2004, Dr. Somani has been in private practice, where he has cultivated a specialized cataract surgery and medical retina practice. He serves as an attending surgeon at two regional hospitals and holds the position of Assistant Professor in the Department of Ophthalmology at the University of Toronto. Throughout his career, Dr. Somani has been actively engaged in various research endeavors aimed at advancing ocular health. He is particularly involved with FORSEE Canada, a charitable organization dedicated to promoting research, education, and outreach in the field of ophthalmology. In addition to his clinical and academic roles, Dr. Somani has demonstrated leadership in health care administration. He has served as the Surgical Lead at Osler's Peel Memorial and as the Medical Director of Uptown Eye Specialists. He has also held several divisional and committee leadership positions within the ophthalmology departments of various health care institutions. Dr. Somani's dedication to excellence has been recognized through numerous awards and honors, including the John Gaby Prize for Best Fellow Research Paper at the University of Toronto. He is a member of several professional organizations, including the Canadian Retina Society, the American Society of Cataract and Refractive Surgery, and the Royal College of Physicians/Surgeons. In addition to his clinical practice and research activities, Dr. Somani is committed to mentoring future generations of ophthalmologists. He has served as a lecturer at the University of Toronto and has been actively involved in post-graduate education and training programs. Dr. Somani's passion for innovation and his dedication to improving patient care underscore his contributions to the field of ophthalmology. His commitment to excellence and his tireless pursuit of knowledge continue to inspire colleagues and patients alike. |
Dr. Rahim Valani, Emergency Medicine |
|
Dr. Rahim Valani is a dedicated researcher with a passion for advancing medical education and emergency medical care. His primary focus revolves around developing innovative curricula and enhancing patient outcomes within emergency departments. Dr. Valani is deeply committed to molding future medical professionals, ensuring they possess the essential skills and knowledge required for success in the fast-paced world of health care. In addition to his work in medical education, Dr. Valani engages in clinical research within emergency medical care. His research is specifically geared towards understanding and improving patient outcomes. He is heavily involved in developing predictive models that not only forecast patient trajectories but also assist in formulating effective treatment strategies. Known for his enthusiasm and collaborative spirit, Dr. Valani is dedicated to driving advancements in health care through research. His goal is to develop outcomes and tools that significantly enhance patient care, benefiting both medical professionals and the patients they serve. At the core of his work lies the connection between educational theory and practical applications in the emergency room, fostering a more informed, efficient, and compassionate health care system. Dr. Valani's qualifications include MD, CCFP-EM, FRCP(EM), M Med Ed, MBA, LLM (Health Law), and he is affiliated with prestigious institutions such as the University of Toronto and McMaster University. |
